SFTPA2 and infection: Toward this: we (a) Infected hTG mice carrying a different SP-A1 or SP-A2 variant or both SP-A1/SP-A2 (co-ex) as well as mice lacking SP-A (i.e., KO) with K. pneumoniae and studied their daily survival over a 14 day period; (b) Rescued K. pneumoniae infected KO mice with exogenous SP-A1 or SP-A2 treatment prior to and/or at the time infection; (c) Carried out pilot binding studies of SP-A1 (6A2) and SP-A2 (1A0) to the AM as well as expression of cell surface proteins from AMs of SP-A1 (6A2) and SP-A2 (1A0) mice.